Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study.

In the primary analysis, more Isa-VRd/Isa-Rd-treated patients achieved minimal residual disease (MRD) negativity and MRD-negative complete response (CR) at any time point than patients receiving VRd followed by Rd.

在主要分析中，接受Isa-VRd/Isa-Rd治疗的患者在任何时间点达到微小残留病灶（MRD）阴性和MRD阴性的完全缓解（CR）的患者数量，超过了接受VRd后继以Rd治疗的患者。

Here, we report landmark analysis results of MRD negativity over time and its impact on clinical outcomes in IMROZ.

在这里，我们报告了IMROZ研究中微小残留病灶（MRD）阴性随时间变化的里程碑分析结果及其对临床结果的影响。

Treatment with Isa-VRd/Isa-Rd led to deeper responses, with higher rates of MRD negativity and MRD-negative CR at the end of induction and during maintenance vs VRd/Rd, up to 60 months of follow-up.

使用Isa-VRd/Isa-Rd治疗可获得更深层次的反应，与VRd/Rd相比，在诱导治疗结束时及维持治疗期间，MRD阴性率和MRD阴性完全缓解（CR）率更高，随访时间长达60个月。

Benefit with Isa-VRd/Isa-Rd was observed across key patient subgroups, including older (>70 years) and frail patients.

在包括年龄较大（>70岁）和虚弱患者在内的关键患者亚组中观察到Isa-VRd/Isa-Rd的益处。

Time to progression (TTP) was significantly prolonged with Isa-VRd/Isa-Rd vs VRd/Rd in patients who converted from MRD negative to MRD positive at any time point.

在任何时间点从微小残留病灶（MRD）阴性转为MRD阳性的患者中，与VRd/Rd相比，Isa-VRd/Isa-Rd显著延长了疾病进展时间（TTP）。

In a landmark analysis of the time of conversion to MRD positivity, TTP in patients who converted from MRD negative at the end of induction to MRD positive also favored Isa-VRd/Isa-Rd.

在对转为最小残留病灶（MRD）阳性时间的里程碑分析中，从诱导治疗结束时的MRD阴性转为MRD阳性的患者的无进展生存期（TTP）也倾向于使用Isa-VRd/Isa-Rd治疗方案。

Evaluating MRD status of patients at >1 time point may therefore be useful to support decisions on treatment selection and treatment continuation/discontinuation.

因此，在一个以上时间点评估患者的MRD状态可能对于支持治疗选择和治疗继续/停止的决策是有用的。

Our findings on the degree of MRD negativity and MRD-negative CR benefit achieved during induction and maintenance by patients receiving Isa-VRd/Isa-Rd vs VRd/Rd extend the IMROZ primary analyses and further support Isa-VRd as standard of care for frontline treatment of transplant-ineligible patients with NDMM.

我们在接受Isa-VRd/Isa-Rd与VRd/Rd治疗的患者中，对诱导和维持期间达到的微小残留病灶（MRD）阴性程度和MRD阴性完全缓解（CR）的益处进行了研究，这些发现扩展了IMROZ主要分析，并进一步支持将Isa-VRd作为不适合移植的初治新诊断多发性骨髓瘤（NDMM）患者的护理标准。

This trial was registered at www.clinicaltrials.gov as #NCT03319667.

该试验已在www.clinicaltrials.gov上注册，注册号为#NCT03319667。